In studies of diet programs and weight-loss surgery, one partner's weight loss went with shared healthier habits in some couples and with criticism or divorce in others. For glucagon-like peptide-1 (GLP-1) drugs such as tirzepatide, couple research offers a single case report, so the drug labels are the firmer guide.
Young people in one survey ranked weight low among threats to a marriage. In that 2018 survey, Al Gharaibeh asked 865 young Emiratis in Sharjah to rate perceived causes of early divorce. Among 15 items on marital intimacy, obesity and excessive weight gain ranked 13th, while carelessness in appearance and hygiene ranked third.
Weight, Health, and Marital Satisfaction
Marriage quality is linked to health and weight, though these studies show associations rather than causation. In a 2014 meta-analysis of 126 studies, Robles and colleagues found that better marital quality went with slightly better health. In a 2013 study, Meltzer and colleagues followed 169 newlywed couples for four years. Spouses who were more satisfied than usual gained more weight.
One spouse's obesity also predicts the other's. In a 2016 cohort study, Cobb and colleagues followed 3,889 middle-aged US spouse pairs for up to 25 years. Among men whose wives became obese, the rate of becoming obese was 1.78 times that of men whose wives did not. Among women, the figure was 1.89. Weight in a marriage is therefore partly shared.
Body Image and Intimacy
Among newlyweds, a wife's view of her own body predicted marital satisfaction beyond her weight. In a 2010 study of 53 newlywed couples, Meltzer and McNulty measured how sexually attractive wives judged themselves. Those judgments accounted for 19% of the variance in wives' marital satisfaction and 6% in husbands', including after accounting for wives' body mass index, a weight-for-height measure.
After bariatric surgery, sexual satisfaction improved for many patients. In a 2019 study, Steffen and colleagues followed 2,036 US adults for five years after surgery. About half of women and men dissatisfied with their sexual life beforehand improved meaningfully at one year and stayed improved at five.
For GLP-1 drugs, the evidence on sexual function is thin. Merhi's 2026 review called the human findings mixed.
When One Partner Loses a Lot of Weight
Bruze and colleagues' 2018 study of two Swedish cohorts found relationships changed in both directions after bariatric surgery. One compared 1,958 patients with 1,912 matched controls with obesity. Within 10 years, 17.1% of partnered patients divorced or separated, against 11.6% of partnered controls. Over the same period, 34.8% of single patients married or began a relationship, against 19.4%.
In Romo and Dailey's 2014 study of 21 US couples in which one partner had lost weight, many adopted healthier habits together. In others, the partner who didn't lose weight was critical. Whether weight loss from a drug has the same effects is unknown.
Couples Who Start a GLP-1 Together
As of October 2026, no controlled trial or cohort study of couples beginning a GLP-1 drug together had been identified. The nearest evidence concerns the ripple effect, weight change in an untreated spouse. Look AHEAD was a US lifestyle trial in adults with type 2 diabetes and excess weight. In 2008, Gorin and colleagues followed untreated spouses of 357 participants for 12 months. Spouses of those in the lifestyle program lost 2.2 kg, against 0.2 kg for spouses of those given only support and education.
The only GLP-1 evidence on couples is Eason and colleagues' 2025 case report of one UK couple. The wife lost 29.2% of her body weight in 32 weeks on tirzepatide. Her husband, who was ineligible for GLP-1 drugs, lost 13.4% of his body weight while she did the household food buying.
Tirzepatide for Couples: What to Expect
For a couple, the key label facts concern side effects, contraception, and pregnancy. Eli Lilly sells two tirzepatide brands with different approvals, Mounjaro for type 2 diabetes and Zepbound for long-term weight reduction alongside diet and activity. Tirzepatide acts on the receptors of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), both gut hormones, and the Zepbound label says it lowers calorie intake.
In that label's pooled trials, nausea affected 25% to 29% of people on tirzepatide and 8% on placebo. Most nausea, vomiting, and diarrhea came during dose increases and became less common over time. The Mounjaro and Zepbound labels both advise anyone using an oral hormonal contraceptive to switch to a non-oral method or add a barrier method. The advice covers four weeks after starting and after each dose increase, and non-oral contraceptives should not be affected. The Zepbound label also warns of possible fetal harm and says to stop the drug once pregnancy is recognized.
Pharmacies have been restricted from copying the approved drug since December 19, 2024, when the Food and Drug Administration (FDA) judged the tirzepatide shortage over. Compounded tirzepatide, mixed by a pharmacy, is not FDA approved, and the FDA does not assess compounded drugs for safety, effectiveness, or quality. By May 31, 2026, it had received more than 730 adverse-event reports linked to compounded tirzepatide. A couple deciding how to obtain tirzepatide is choosing between reviewed and unreviewed products.
Talking About Weight Without Blame
The way partners discuss weight matters more than whether they discuss it. Lawrence and colleagues' 2023 survey covered 8,100 weight-management program members in six countries, all of whom had experienced weight stigma. Between 40% and 57% named a spouse or partner as a source, depending on the country. In a 2016 diary study, Dailey and colleagues followed 53 adults managing their weight. Those who saw a partner as both accepting and challenging reported better progress on weight and diet goals.
A GLP-1 drug can add a further judgment about how the weight was lost. In Post and colleagues' 2026 experiment, 402 women read about a fictional woman who had lost 15% of her weight. She was rated with more stigma when a GLP-1 drug, not diet and exercise, had produced the loss. Stronger belief that the drug was a shortcut explained the difference. In a marriage, that view can raise the question of whether using a weight-loss drug is cheating.
The existing couple studies measured household food and partner talk, not any drug. Until couples starting tirzepatide are studied, its effect on a marriage will likely depend on those habits as well as on the drug.
Sources
- Marriage and weight: Al Gharaibeh, Eur J Soc Sci, 2018; Robles et al., Psychol Bull, 2014; Meltzer et al., Health Psychol, 2013; Cobb et al., Am J Epidemiol, 2016
- Body image and intimacy: Meltzer and McNulty, J Fam Psychol, 2010; Steffen et al., JAMA Surg, 2019; Merhi, Sex Med Rev, 2026
- Weight loss and relationships: Bruze et al., JAMA Surg, 2018; Romo and Dailey, Health Commun, 2014
- Couples and GLP-1 use: Gorin et al., Int J Obes (Look AHEAD), 2008; Eason et al., Obes Pillars, 2025
- Tirzepatide: Zepbound label, 2026; Mounjaro label, 2026; FDA Clarifies Policies for Compounders, 2026; FDA Concerns with Unapproved GLP-1 Drugs, 2026
- Talking about weight: Lawrence et al., Obesity, 2023; Dailey et al., Health Commun, 2016; Post et al., Stigma Health, 2026